Related Experiment Video

Updated: Oct 8, 2026

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific

D J Nelson1, S Mukherjee, C Bundell

  • 1Department of Medicine, University of Western Australia, Nedlands, Queen Elizabeth II Medical Center, Perth, Western Australia, Australia. delian@cyllene.uwa.edu.au

Journal of Immunology (Baltimore, Md. : 1950)
|April 21, 2001
PubMed

Insights

Tumor cells evade immune attack not due to antigen presentation or T-cell activation, but because the tumor microenvironment prevents cytotoxic T-lymphocyte (CTL) from killing cancer cells. This immune evasion occurs early in tumor development.

Area of Science:

  • Immunology
  • Cancer Biology
  • Tumor Microenvironment

Background:

  • Nonimmunogenic tumors often evade immune surveillance.
  • Understanding immune evasion mechanisms is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

  • To investigate whether antigen presentation or cytotoxic T-lymphocyte (CTL) "arming" is impaired in nonimmunogenic tumors.
  • To identify the specific phase of the immune response where tumor growth fails to be inhibited.

Main Methods:

  • Established a murine tumor model expressing intracellular ovalbumin (OVA).
  • Selected a clone (cOVA-9) susceptible to CTL lysis throughout tumor growth.
  • Evaluated in vivo antigen cross-presentation and CTL activity in tumor-draining lymph nodes.

Main Results:

  • Nonimmunogenic tumors grew similarly to parental lines, even after vaccination.
  • Potent, specific CTLs were generated, and antigen cross-presentation persisted.
  • Despite active CTLs, tumor-associated antigen-presenting cells (APCs) were not lysed.

Conclusions:

  • Tumor-draining APCs are functional in antigen cross-presentation and CTL arming.
  • Immune evasion occurs in the effector phase within the tumor itself, not during induction.
  • Failure to prevent tumor growth is linked to the tumor microenvironment's impact on CTL function before tumor matrix establishment.

More Related Videos

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...